

To, The Manager Listing Department, **The National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA** 

Sub: Compliance with requirement of Good Manufacturing Practice Guideline (GMP) of the Drug Administration of Vietnam

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we, Zota Health Care Limited (the "Company") would like to inform you that as per the Official Letter No. 15966 / QLD-CL dated October 16, 2020 of the Drug Administration of Vietnam, the Company's plant situated at Surat Special Economic Zone has complied with the requirement of Good Manufacturing Practice Guideline (GMP) of Vietnam.

The aforementioned notification for GMP compliance is valid up to 16<sup>th</sup> February, 2023 and the same is renewable. After getting this clearance the path for exporting our products in Vietnam is now cleared.

Further, we have already filed application for product approval for 30 products in Vietnam; post approval of the same, Company shall start exporting products in Vietnam.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya (Company Secretary & Compliance Officer) Place: Surat



## Registered Office :

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com CIN : L24231GJ2000PLC038352

## Plant :

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 39<sup>24</sup> 230 (Guj.) India Ph: +91 261 2397122